公开(公告)号：EP4422614A1

公开(公告)日：2024-09-04

申请号：EP22813428.4

申请日：2022-10-27

申请人： Société des Produits Nestlé S.A.

发明人： TROVO, Laura ,  STEINER, Pascal ,  PAN, Yuanlong ,  PREITNER, Nicolas

IPC分类号： A61K31/12 ,  A61K31/132 ,  A61K31/202 ,  A61K31/37 ,  A61P25/00 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61K9/00

CPC分类号： A61P25/28 ,  A61P25/22 ,  A61P25/24 ,  A61P25/00 ,  A61K31/132 ,  A61K31/37 ,  A61K31/202 ,  A61K31/12

公开(公告)号：EP3634966B1

公开(公告)日：2024-06-05

申请号：EP18813214.6

申请日：2018-06-05

IPC分类号： C07D493/04 ,  C07D491/22 ,  A61K31/519 ,  A61K31/37 ,  A61P35/00

CPC分类号： C07D493/04 ,  A61P35/00 ,  A61K45/06

公开(公告)号：EP4346902A1

公开(公告)日：2024-04-10

申请号：EP22741839.9

申请日：2022-06-03

申请人： Council of Scientific & Industrial Research

发明人： KOTAMRAJU, Srigiridhar ,  BATHULA, Surendar Reddy ,  SHAIKH, Altab ,  NEELI, Praveen Kumar ,  SRAVYA, Panangipalli ,  BANERJEE, Rajkumar ,  THENNATI, Rajamannar ,  GAJALAKSHMI, Singuru

IPC分类号： A61K47/54 ,  A61P35/00 ,  C12N15/113 ,  C07F9/54 ,  A61K31/37

公开(公告)号：EP4223293A1

公开(公告)日：2023-08-09

申请号：EP21874791.3

申请日：2021-04-20

申请人： Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

发明人： INOUE Satoshi ,  TAKAYAMA Ken-ichi ,  OSADA Hiroyuki ,  KONDOH Yasumitsu

IPC分类号： A61K31/37 ,  A61K31/404 ,  A61K31/405 ,  A61K31/453 ,  A61K31/5383 ,  A61P13/08 ,  A61P15/00 ,  A61P35/00

摘要： The object of the present invention is to provide a therapeutic agent for treating hormone therapy-resistant, treatment-resistant cancers, and a method of the treatment of hormone therapy-resistant, treatment-resistant cancers.
The problem can be solved by a pharmaceutical composition including a compound represented by the formula (1) or a salt thereof or a compound represented by the formula (2) or (3) or a salt thereof, as an active ingredient for treating prostate cancer. Furthermore, the pharmaceutical composition of the present invention can effectively treat not only hormone therapy-resistant prostate cancer or breast cancer but also non-hormone therapy-resistant prostate cancer or breast cancer and Castration-resistant prostate cancer or treatment-resistant breast cancer caused by other mechanisms.

公开(公告)号：EP4199909A1

公开(公告)日：2023-06-28

申请号：EP21763033.4

申请日：2021-08-09

申请人： The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth ,  University College Dublin, National University of Ireland, Dublin

发明人： STOCKER, Michael ,  FERGUSON, Steven ,  HEALY, Anne Marie

IPC分类号： A61K9/16 ,  A61K31/138 ,  A61K31/192 ,  A61K31/37 ,  C07D311/56

公开(公告)号：EP4164631A1

公开(公告)日：2023-04-19

申请号：EP21825169.2

申请日：2021-06-07

申请人： Immunolight, LLC.

发明人： BOURKE, Frederic A., Jr. ,  WALDER, Harold ,  FATHI, Zakaryae

IPC分类号： A61K31/37 ,  A61K31/409 ,  A61K39/00 ,  A61K41/00 ,  A61K45/06 ,  A61K49/00

公开(公告)号：EP4138816A1

公开(公告)日：2023-03-01

申请号：EP21793651.7

申请日：2021-03-17

申请人： The University of Hong Kong

发明人： WANG, Weiping ,  LONG, Kaiqi

IPC分类号： A61K31/37 ,  C08G69/00 ,  A61K9/00 ,  A61P35/00

公开(公告)号：EP4085906A1

公开(公告)日：2022-11-09

申请号：EP21305586.6

申请日：2021-05-06

申请人： UNIVERSITE DE BORDEAUX ,  Centre Hospitalier Universitaire de Bordeaux ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM

发明人： ROSSIGNOL, Rodrigue ,  DARD, Laetitia ,  LACOMBE, Didier ,  DIAS AMOEDO, Nivea

IPC分类号： A61K31/195 ,  A61K31/216 ,  A61K31/37 ,  A61K45/06 ,  A61P9/00 ,  A61P43/00

摘要： The present invention belongs to the field of medicine, and more precisely to the field of medecine useful in the treatment of cardiac diseases with contributing mitochondrial dysfunction.
The present invention relates to a composition a pharmaceutical composition comprising a PPAR-modulator and an urolithin derivative of formula I:

wherein R 1 , R 2 and R 3 independently represents H or OH and its use thereof in the treatment of various cardiac diseases linked to cardiac diseases with contributing mitochondrial dysfunction.

公开(公告)号：EP4059496A1

公开(公告)日：2022-09-21

申请号：EP21305335.8

申请日：2021-03-18

申请人： INSTITUT PASTEUR

发明人： RICCHETTI, Miria.

IPC分类号： A61K31/35 ,  A61K31/353 ,  A61K31/37 ,  A61K31/428 ,  A61K31/47 ,  A61K31/635 ,  A61P31/02 ,  A61P25/00

摘要： The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-Pyp5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2- Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).

公开(公告)号：EP4056573A1

公开(公告)日：2022-09-14

申请号：EP20881417.8

申请日：2020-10-30

申请人： PRG S&Tech Inc.

发明人： PARK, Bum-Joon

IPC分类号： C07D493/04 ,  A61K31/37 ,  A61P21/00 ,  A23L33/10

摘要： The present invention relates to a use of a novel compound, for preventing, improving or treating amyotrophic lateral sclerosis (ALS). The present inventors have found that SOD1 aggregation is one of the important causes of ALS, and have proposed the possibility that WT-SOD1 aggregation, caused by suppressing the regulation of intracellular stress or TDP-43, may be a cause of sALS. In addition, the present inventors have discovered the novel compound PRG-A-01(SLC-B036) as a SOD1 aggregation and misfolding inhibitor. The compound exhibited a protective effect against muscle weakness and movement disorder in an ALS mouse model. According to the result of a histological analysis, intraspinal nerves were maintained by means of a treatment using PRG-A-01(SLC-B036). In addition, the present inventors have obtained a candidate compound (PRG-A-04) which can be a more optimized drug. Consequently, the compound of the present invention may be usefully employed in developing a therapeutic agent for ALS.